Immunome (NASDAQ:IMNM) Hits New 52-Week High – What’s Next?

Shares of Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week high during trading on Tuesday . The stock traded as high as $27.20 and last traded at $26.9050, with a volume of 128841 shares. The stock had previously closed at $26.14.

Wall Street Analyst Weigh In

IMNM has been the topic of several recent research reports. Stephens increased their target price on shares of Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a report on Monday, November 17th. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research note on Thursday, January 22nd. Leerink Partners set a $40.00 target price on Immunome in a report on Monday, December 15th. Finally, Evercore ISI raised their price target on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Immunome currently has an average rating of “Moderate Buy” and a consensus price target of $31.00.

Immunome Stock Down 7.3%

The company has a market capitalization of $2.25 billion, a PE ratio of -8.35 and a beta of 2.32. The stock’s fifty day moving average price is $21.78 and its two-hundred day moving average price is $15.88.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, equities research analysts forecast that Immunome, Inc. will post -2.21 EPS for the current year.

Insider Buying and Selling

In related news, CEO Clay B. Siegall bought 4,729 shares of the company’s stock in a transaction dated Tuesday, December 30th. The stock was purchased at an average cost of $21.15 per share, with a total value of $100,018.35. Following the transaction, the chief executive officer owned 665,254 shares in the company, valued at approximately $14,070,122.10. This trade represents a 0.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Philip Tsai purchased 10,000 shares of Immunome stock in a transaction that occurred on Friday, December 19th. The shares were bought at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the transaction, the insider directly owned 43,300 shares of the company’s stock, valued at $887,217. This trade represents a 30.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 68,518 shares of company stock valued at $1,453,958 over the last quarter. 7.69% of the stock is owned by company insiders.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Nan Fung Trinity HK Ltd. grew its holdings in shares of Immunome by 20.7% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 714,553 shares of the company’s stock worth $15,349,000 after acquiring an additional 122,450 shares during the period. Strs Ohio bought a new stake in shares of Immunome during the fourth quarter valued at approximately $64,000. Vanguard Group Inc. grew its stake in Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the period. Arizona State Retirement System raised its holdings in Immunome by 27.1% in the fourth quarter. Arizona State Retirement System now owns 26,104 shares of the company’s stock worth $561,000 after purchasing an additional 5,568 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Immunome in the fourth quarter worth $3,652,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.